Clinical Trials Browser

Phase 1/2 × Neuroectodermal Tumors, Primitive × surufatinib × Clear all

NCT02549937 2024-07-10

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Phase 1/2 Completed

130 enrolled 30 charts

EndocrineSarcoma

Carcinoid Tumor, Neoplasms, Sarcoma, Neuroectodermal Tumors, Primitive